ArticleBiosensors2019
Development of a Label-Free Electrochemical Aptasensor for the Detection of Tau381 and its Preliminary Application in AD and Non-AD Patients' Sera.
Article in Biosensors, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Label-Free Electrochemical Biosensors: An Updated Perspective Focused on Genosensing, Multiplexing, and Commercial Potential.Biosensors · 2026Review
- Recent molecular insights and biosensor-based diagnostic technologies for hyperphosphorylated Tau in Alzheimer's disease.Alzheimer's research & therapy · 2025Review
- Therapeutic Oligonucleotides for Neurodegenerative Diseases: Aptamer Strategies and Clay Nanoparticle-Based Delivery.Chemical record (New York, N.Y.) · 2025Review
- The Diagnostic and Therapeutic Potential of Oligonucleotide Aptamers in Alzheimer's Disease.Cells · 2025Review
- Electrochemical Immunosensor Using COOH-Functionalized 3D Graphene Electrodes for Sensitive Detection of Tau-441 Protein.Biosensors · 2025Article
- Article
- Recent Advances in Electrochemical Biosensors for Neurodegenerative Disease Biomarkers.Biosensors · 2025Review
- Tau- and α-synuclein-targeted gold nanoparticles: applications, opportunities, and future outlooks in the diagnosis and therapy of neurodegenerative diseases.Journal of nanobiotechnology · 2024Review
- Nucleic Acid Aptamer-Based Biosensors: A Review.Biomedicines · 2023Review
- Application of Pt@ZIF-8 nanocomposite-based electrochemical biosensor for sensitive diagnosis of tau protein in Alzheimer's disease patients.Scientific reports · 2023Article
- A New Optical Interferometric Biosensing System Enhanced with Nanoparticles for Alzheimer's Disease in Serum.Biosensors · 2023Article
- Tau Protein Biosensors in the Diagnosis of Neurodegenerative Diseases.Advanced pharmaceutical bulletin · 2023Review
- Aptamer-based rapid diagnosis for point-of-care application.Microfluidics and nanofluidics · 2023Review
- Portable Vertical Graphene@Au-Based Electrochemical Aptasensing Platform for Point-of-Care Testing of Tau Protein in the Blood.Biosensors · 2022Article
- An Electrochemiluminescence Biosensor for the Detection of Alzheimer's Tau Protein Based on Gold Nanostar Decorated Carbon Nitride Nanosheets.Molecules (Basel, Switzerland) · 2022Article
- Clinically oriented Alzheimer's biosensors: expanding the horizons towards point-of-care diagnostics and beyond.RSC advances · 2021Review
- Electrochemical sensing of blood proteins for mild traumatic brain injury (mTBI) diagnostics and prognostics: towards a point-of-care application.RSC advances · 2021Review
- From Small Molecules Toward Whole Cells Detection: Application of Electrochemical Aptasensors in Modern Medical Diagnostics.Sensors (Basel, Switzerland) · 2021Review
- The Microfluidic Toolbox for Analyzing Exosome Biomarkers of Aging.Molecules (Basel, Switzerland) · 2021Review
- Electrochemical Aptasensors: Current Status and Future Perspectives.Diagnostics (Basel, Switzerland) · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
Abstract
The electrochemical aptamer sensor has been designed for detecting tau381, a critical biomarker of Alzheimer's disease in human serum. The aptasensor is obtained by immobilizing the aptamer on a carboxyl graphene/thionin/gold nanoparticle modified glassy-carbon electrode. As a probe and bridge molecule, thionin connected carboxyl graphene and gold nanoparticles, and gave the electrical signal. Under optimal conditions, the increment of differential pulse voltammetry signal increased linearly with the logarithm of tau381 concentration in the range from 1.0 pM to 100 pM, and limit of detection was 0.70 pM. The aptasensor reliability was evaluated by determining its selectivity, reproducibility, stability, detection limit, and recovery. Performance analysis of the tau381 aptasensor in 10 patients' serum samples showed that the aptasensor could screen patients with and without Alzheimer's disease. The proposed aptasensor has potential for use in clinically diagnosing Alzheimer's disease in the early stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.